News 03.10.2019 Zurich-Schlieren, October 3, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced that the first patient has been enrolled and dosed in a Phase 1 first-in-human study of MP0310 as a single agent in patients...
Internal events
Event date: 31.10.2019
Researchers across the globe face common barriers in translational research that can delay the development of new interventions for patients in need.
This seminar will focus on describing the strategies and benefits of implementing a stage-gate approach in early non clinical development and for Phase 1 clinical development.
More information and program
Time:...
External events
Event date: 01.10.2019
Date&time:
Tuesday, 1 October 2019, 6:00PM - 10:00PM EST
Location:
Pfizer, Schärenmoosstrasse 99, Zurich
Cost:
Member $30
Guest $45
Register:
http://bit.ly/ 2NWjJ4b
The healthcare industry is continually undergoing changes, and the current climate is unparalleled. This event will explore the human reactions to change by understanding the relationship between basic human needs, silent stress and health.
Jessica Lockhart, a leading...
News 24.09.2019 Schlieren (Zurich), Switzerland, September 24, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today announces the full commercial launch of MagnetOs™ and the company’s first attendance as an exhibitor at NASS, the world’s largest spine meeting and exhibition. During the meeting, the commercial team will be...
News 09.09.2019 DUBLIN, IRELAND – SEPT 9, 2019 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and...